Cytek Biosciences, Inc. 8-K

What Happened

• Cytek Biosciences, Inc. (CTKB) announced its financial results for the quarter and full year ended December 31, 2025 via a press release dated February 26, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed the same day (Item 2.02, Results of Operations and Financial Condition).

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Reporting period: Quarter and full year ended December 31, 2025.
• Disclosure type: Item 2.02 — results of operations and financial condition; press release furnished as Exhibit 99.1.
• Interactive data: Cover Page Interactive Data File included as Exhibit 104 (Inline XBRL).

Why It Matters

• The press release provides the company’s latest reported financial performance for Q4 and FY 2025, which investors use to assess revenue trends, profitability, and management commentary.
• Because the results were furnished on Form 8-K, investors and analysts should review the Exhibit 99.1 press release and the Inline XBRL data for specifics (revenue, net income/loss, and any management discussion) to update models and investment decisions.